According to the Zhī tōng Cái jīng app, Hepalink (09989) rose more than 14%, as of the time of publication, up 14.2% at HKD 3.76, with a turnover of HKD 1.9479 million.
On the news front, Hepalink announced that it is expected to achieve a net income attributable to shareholders of the listed company of approximately RMB 0.642 billion to 0.735 billion in the first half of 2024, a year-on-year increase of 420.70%-495.72%; the expected non-net profit will be approximately RMB 0.308 billion-0.401 billion, a year-on-year increase of 286.96%-403.20%.
The Company pointed out that during the reporting period, its main product, Enoxaparin Sodium preparations, maintained growth in sales volume in markets such as Europe, the United States, and China, further increasing global market share. At the same time, the gross margin of the formulated products has been improved under the joint effect of good price system maintenance, improved cost control efficiency, and reduced raw material costs, after excluding the price impact of group purchases in the Chinese market compared with the same period last year.
